首页> 外文期刊>Biomedicine & pharmacotherapy =: Biomedecine & pharmacotherapie >The failure of HAART to cure the HIV-1/AIDS complex. Suggestions to add integrase inhibitors as complementary virostatics, and to replace their continuous long combination applications by short sequences differing by drug rotations.
【24h】

The failure of HAART to cure the HIV-1/AIDS complex. Suggestions to add integrase inhibitors as complementary virostatics, and to replace their continuous long combination applications by short sequences differing by drug rotations.

机译:HAART无法治愈HIV-1 / AIDS复合体。建议添加整合酶抑制剂作为补充的抑菌剂,并用因药物轮换而异的短序列代替其连续的长效组合应用。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

While the intensive virostatic combinations applied according to the conventional models (such as HAART), based only on the attacks of two HIV-1 targets, retrotranscriptase and protease, and applied in a long and continuous fashion, a) are notably toxic, b) do not correct completely the abnormal immunologic parameters, and c) are followed by particularly severe and poorly sensitive relapses in case of discontinuation, we propose to the 'AIDS treatment headquarters' to include in their failing strategy the two original features which we have included in the treatment of a cohort of a dozen patients, treatment applied at all but one AIDS stage. We attack one more HIV-1 target than the conventional protocols do, by adding inhibitors of integrase; we apply the combinations of virostatics, comprising inhibitors of the three targets, in short sequences (of 3 weeks), between which the analogues are changed inside each series. The first patient of the cohort started his treatment 8.5 years ago, and the entries of the others into it have been at random and not randomized. All patients are alive today and in excellent condition.
机译:根据常规模型(如HAART),仅根据两个HIV-1靶标(逆转录酶和蛋白酶)的攻击并长时间连续施用的强效病毒抑制剂组合,a)明显有毒,b)不能完全纠正异常的免疫学参数,并且c)在停药的情况下会出现特别严重且敏感性较差的复发,我们建议“艾滋病治疗总部”在其失败策略中纳入我们所包括的两个原始特征一个队列的十几名患者的治疗,除一个艾滋病阶段外,全部都采用了治疗。通过添加整合酶抑制剂,我们可以比常规方案攻击更多的HIV-1目标。我们在短时间内(3周内)应用了包含三个靶标抑制剂的抑菌剂组合,在这两个序列之间,类似物在每个系列中都发生了变化。该队列的第一位患者于8.5年前开始接受治疗,其他患者随机进入且未随机进入。所有患者今天都还活着,并且状况良好。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号